157 related articles for article (PubMed ID: 36878650)
1. Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada.
Movahedi M; Choquette D; Coupal L; Cesta A; Li X; Keystone EC; Bombardier C; Investigators O
BMJ Open; 2023 Mar; 13(3):e063198. PubMed ID: 36878650
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort.
Movahedi M; Hepworth E; Mirza R; Cesta A; Larche M; Bombardier C
Semin Arthritis Rheum; 2020 Oct; 50(5):915-922. PubMed ID: 32911288
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
5. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
Jinno S; Onishi A; Dubreuil M; Hashimoto M; Yamamoto W; Murata K; Takeuchi T; Kotani T; Maeda Y; Ebina K; Son Y; Amuro H; Hara R; Katayama M; Saegusa J
Arthritis Res Ther; 2021 Apr; 23(1):116. PubMed ID: 33858490
[TBL] [Abstract][Full Text] [Related]
7. Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.
Ogawa Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Takagi H; Hanabayashi M; Funahashi K; Hayashi M; Tsuboi S; Asai S; Asai N; Matsumoto T; Sobue Y; Ishiguro N; Kojima T
Clin Rheumatol; 2019 Oct; 38(10):2757-2763. PubMed ID: 31179526
[TBL] [Abstract][Full Text] [Related]
8. Physician- and Patient-reported Effectiveness Are Similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data From a Rheumatoid Arthritis Registry.
Movahedi M; Cesta A; Li X; Keystone EC; Bombardier C;
J Rheumatol; 2022 May; 49(5):447-453. PubMed ID: 35169051
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
Aymon R; Mongin D; Bergstra SA; Choquette D; Codreanu C; De Cock D; Dreyer L; Elkayam O; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Koca SS; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rodrigues A; Rotar Z; Strangfeld A; Verschueren P; Westermann R; Zavada J; Courvoisier DS; Finckh A; Lauper K
Ann Rheum Dis; 2024 Mar; 83(4):421-428. PubMed ID: 38071508
[TBL] [Abstract][Full Text] [Related]
11. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
[TBL] [Abstract][Full Text] [Related]
13. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
14. Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure.
Min HK; Kim HR; Lee SH; Hong YS; Kim MY; Park SH; Kang KY
Rheumatology (Oxford); 2021 Dec; 60(12):5743-5752. PubMed ID: 33725088
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
[TBL] [Abstract][Full Text] [Related]
16. Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry.
Bergstra SA; Allaart CF; Vega-Morales D; De Buck M; Murphy E; Salomon Escoto K; Huizinga TWJ
RMD Open; 2020 Jun; 6(2):. PubMed ID: 32506054
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study.
Paroli M; Becciolini A; Bravi E; Andracco R; Nucera V; Parisi S; Ometto F; Lumetti F; Farina A; Del Medico P; Colina M; Lo Gullo A; Ravagnani V; Scolieri P; Larosa M; Priora M; Visalli E; Addimanda O; Vitetta R; Volpe A; Bezzi A; Girelli F; Molica Colella AB; Caccavale R; Di Donato E; Adorni G; Santilli D; Lucchini G; Arrigoni E; Platè I; Mansueto N; Ianniello A; Fusaro E; Ditto MC; Bruzzese V; Camellino D; Bianchi G; Serale F; Foti R; Amato G; De Lucia F; Dal Bosco Y; Foti R; Reta M; Fiorenza A; Rovera G; Marchetta A; Focherini MC; Mascella F; Bernardi S; Sandri G; Giuggioli D; Salvarani C; Franchina V; Molica Colella F; Ferrero G; Ariani A
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629770
[No Abstract] [Full Text] [Related]
18. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.
Bechman K; Oke A; Yates M; Norton S; Dennison E; Cope AP; Galloway JB
Rheumatology (Oxford); 2020 Sep; 59(9):2563-2571. PubMed ID: 31998962
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
[TBL] [Abstract][Full Text] [Related]
20. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Etani Y; Maeda Y; Okita Y; Hirao M; Yamamoto W; Hashimoto M; Murata K; Hara R; Nagai K; Hiramatsu Y; Son Y; Amuro H; Fujii T; Okano T; Ueda Y; Katayama M; Okano T; Tachibana S; Hayashi S; Kumanogoh A; Okada S; Nakata K
RMD Open; 2023 Aug; 9(3):. PubMed ID: 37597846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
